Skip to main content
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. — Investor Relations & Filings

Ticker · ORKA ISIN · US6876041087 US Manufacturing
Open in API
Filings indexed 997 across all filing types
Latest filing 2024-10-07 Proxy Solicitation & In…
Country US United States of America
Listing US ORKA

About Oruka Therapeutics, Inc.

https://orukatx.com/

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel biologics for chronic skin diseases and other inflammatory conditions. The company applies advanced antibody engineering to validated modes of action to create potentially best-in-class monoclonal antibodies. Its lead program, ORKA-001, targets the IL-23 cytokine for the treatment of moderate-to-severe plaque psoriasis. Oruka's mission is to redefine the standard of care by developing treatments that achieve high rates of complete disease clearance with a significantly reduced dosing frequency, potentially requiring only one or two doses per year.

Recent filings

Filing Released Lang Actions
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, as indicated by the header and the text. It is a preliminary proxy statement for a Special Meeting of Stockholders scheduled for November 14, 2024. The document includes details about the meeting agenda, voting instructions, and corporate actions requiring shareholder approval, such as approval of issuance of shares upon conversion of preferred stock and adjournment of the meeting. The document is not an annual report, earnings release, or financial report but rather a solicitation of shareholder votes and information about the meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just an announcement of its availability. Therefore, the correct classification is PSI with high confidence.
2024-10-07 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-10-07 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 3, 2024, for Oruka Therapeutics, Inc. The content focuses on the departure and appointment of directors or officers, specifically amended employment agreements for the CEO and Senior VP of Finance, detailing severance and compensation terms. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The primary subject is changes in senior management agreements, which fits the category of Board/Management Information filings. The document length is 6744 characters, which is sufficient to contain substantive information rather than a mere announcement. Therefore, the appropriate classification is MANG (Board/Management Information).
2024-10-04 English
AMENDMENT NO. 1 TO SCHEDULE 13D
Major Shareholding Notification
2024-09-13 English
Director's Dealing 2024
Director's Dealing
2024-09-13 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content details a private placement financing agreement, including the issuance of common stock, preferred stock, and warrants, as well as related agreements such as a Registration Rights Agreement and a Certificate of Designation. It also includes information about the securities purchase agreement, amendments to articles of incorporation, and press releases related to the financing and company updates. There are no comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. The document primarily announces a capital raising event and related agreements, which fits the definition of a Capital/Financing Update (CAP). The length and detail confirm it is not a brief announcement but a substantive filing about financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-09-13 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.